QDEL
QuidelOrtho·NASDAQ
--
--(--)
--
--(--)
QDEL fundamentals
QuidelOrtho (QDEL) released its earnings on Feb 11, 2026: revenue was 723.60M (YoY +2.23%), beat estimates; EPS was 0.46 (YoY -26.98%), beat estimates.
Revenue / YoY
723.60M
+2.23%
EPS / YoY
0.46
-26.98%
Report date
Feb 11, 2026
QDEL Earnings Call Summary for Q4,2025
- 2025 Financial Success: $2.73B revenue, 22% EBITDA margin, $597M adjusted EBITDA.
- Labs Growth Engine: 6% annual growth, clinical chemistry and immunoassay expansion.
- Cost Savings Impact: $140M savings, 5% opex reduction, 240bps margin expansion.
- 2026 Outlook: $2.7B-$2.9B revenue, $630M-$670M EBITDA, $140M free cash flow.
- LEX Launch: FDA clearance nearing, 2026 launch with minimal near-term revenue.
- China Growth: Low single digits guided for 2026, offsetting VBP uncertainty.
- R&D Momentum: VITROS 450, new platforms, and Results Manager middleware driving innovation.
EPS
Actual | 0.93 | 1.55 | 5.33 | 10.78 | 4.09 | 0.75 | 5.36 | 7.29 | 11.66 | 2.34 | 1.85 | 1.76 | 1.8 | 0.26 | 0.9 | 1.17 | 0.44 | -0.07 | 0.85 | 0.63 | 0.74 | 0.12 | 0.8 | 0.46 | ||||||||||
Forecast | 0.7533 | 0.9504 | 4.6198 | 9.936 | 4.495 | 1.2033 | 3.524 | 5.6076 | 9.8912 | 2.6835 | 0.7409 | 1.4266 | 1.4928 | 0.2787 | 0.5975 | 2.0384 | 0.3901 | -0.2331 | 0.271 | 0.5907 | 0.5866 | 0.0015 | 0.5149 | 0.4217 | ||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +23.46% | +63.09% | +15.37% | +8.49% | -9.01% | -37.67% | +52.10% | +30.00% | +17.88% | -12.80% | +149.70% | +23.37% | +20.58% | -6.71% | +50.63% | -42.60% | +12.79% | +69.97% | +213.65% | +6.65% | +26.15% | +7900.00% | +55.37% | +9.08% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 174.65M | 201.75M | 476.06M | 809.20M | 375.34M | 176.61M | 509.74M | 636.87M | 1.00B | 613.40M | 783.80M | 866.50M | 846.10M | 665.10M | 744.00M | 742.60M | 711.00M | 637.00M | 727.10M | 707.80M | 692.80M | 613.90M | 699.90M | 723.60M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 157.49M | 189.79M | 450.41M | 810.29M | 400.76M | 174.38M | 376.90M | 540.90M | 891.08M | 768.24M | 719.60M | 770.57M | 778.03M | 615.11M | 691.90M | 796.91M | 693.24M | 613.51M | 642.16M | 699.16M | 689.64M | 611.14M | 669.33M | 700.73M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +10.90% | +6.31% | +5.69% | -0.13% | -6.34% | +1.28% | +35.24% | +17.74% | +12.48% | -20.15% | +8.92% | +12.45% | +8.75% | +8.13% | +7.53% | -6.81% | +2.56% | +3.83% | +13.23% | +1.24% | +0.46% | +0.45% | +4.57% | +3.26% |
Earnings Call
You can ask Aime
What were the key takeaways from QuidelOrtho's earnings call?What guidance did QuidelOrtho's management provide for the next earnings period?Did QuidelOrtho beat or miss consensus estimates last quarter?What is the revenue and EPS growth rate for QuidelOrtho year over year?What factors drove the changes in QuidelOrtho's revenue and profit?What is the market's earnings forecast for QuidelOrtho next quarter?What does QuidelOrtho do and what are its main business segments?What is QuidelOrtho's latest dividend and current dividend yield?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
